Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
23 "Dong Bok Shin"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
Original Articles
S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat. 2019;51(1):1-11.   Published online February 5, 2018
DOI: https://doi.org/10.4143/crt.2018.028
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We conducted a randomized, multicenter, phase III trial to compare S-1 plus docetaxel (DS) with S-1 plus cisplatin (SP) as adjuvant chemotherapy for stage III gastric cancer patients.
Materials and Methods
Stage III gastric cancer patients who had received curative gastrectomy with D2 lymphadenectomy were randomized into equal groups to receive adjuvant chemotherapy of eight cycles of DS (S-1 70 mg/m2 /day on days 1-14 plus docetaxel 35 mg/m2 on days 1 and 8) every 3 weeks or SP (S-1 70 mg/m2 /day on days 1-14 plus cisplatin 60 mg/m2 on day 1) every 3 weeks. The primary endpoint was 3-year disease-free survival (DFS) rate.
Results
Between November 2010 and July 2013, 153 patients (75 patients to DS and 78 patients to SP) were enrolled from 8 institutions in Korea. After the capecitabine plus oxaliplatin was approved based on the CLASSIC study, itwas decided to close the study early. With a median follow-up duration of 56.9 months, the 3-year DFS rate between two groups was not significantly different (49.14% in DS group vs. 52.5% in SP group). The most common grade 3-4 adverse event was neutropenia (42.7% in DS and 38.5% in SP, p=0.351). SP group had more grade 3-4 anemia (1.3% vs. 11.5%, p=0.037), whereas grade 3-4 hand-foot syndrome (4.1% vs. 0%, p=0.025) and mucositis (10.7% vs. 2.6%, p=0.001) were more common in DS group. Fifty-one patients (68%) in DS group and 52 (66.7%) in SP group finished planned treatment.
Conclusion
Our findings suggest that SP or DS is an effective and tolerable option for patients with curatively resected stage III gastric cancer.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
    Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • A novel method of bedside hyperthermic intraperitoneal chemotherapy as adjuvant therapy for stage-III gastric cancer
    Lili Liu, Li Sun, Ning Zhang, Cheng-gong Liao, Haichuan Su, Jie Min, Yang Song, Xue Yang, Xiaofeng Huang, Dongxu Chen, Yu Chen, Hong-wei Zhang, Helong Zhang
    International Journal of Hyperthermia.2022; 39(1): 239.     CrossRef
  • Comment on “post-discharge oral nutritional supplements with dietary advice in patients at nutritional risk after surgery for gastric cancer: A randomized clinical trial”
    Qiang Hu, Yuanshui Sun
    Clinical Nutrition.2021; 40(3): 1438.     CrossRef
  • THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
    A. A. Bobryshev, M. M. Davudov, M. N. Narimanov, S. B. Polycarpova, V. Y. Kirsanov, V. N. Blindar
    Siberian journal of oncology.2021; 20(1): 133.     CrossRef
  • Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
    Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
    Surgical Oncology.2021; 38: 101599.     CrossRef
  • Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis
    Chih-Chieh Yen, Yan-Shen Shan, Ying-Jui Chao, Ting-Kai Liao, I-Shu Chen, Hsuan-Yi Huang, I-Ting Liu, Chia-Jui Yen
    BMC Cancer.2021;[Epub]     CrossRef
  • Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?
    Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, Maria Alessandra Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, Carmelo Pozzo
    Cancers.2020; 12(7): 1749.     CrossRef
  • A systematic review and network meta-analysis protocol of adjuvant chemotherapy regimens for resected gastric cancer
    Long Ge, Liangying Hou, Qingxia Yang, Yiting Wu, Xiue Shi, Jiang Li, Kehu Yang
    Medicine.2019; 98(7): e14478.     CrossRef
  • Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
    Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Cancers.2019; 11(4): 530.     CrossRef
  • COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
    Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Cutting-edge evidence of adjuvant treatments for gastric cancer
    Dai Shimizu, Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto
    Expert Review of Gastroenterology & Hepatology.2018; 12(11): 1109.     CrossRef
  • 13,050 View
  • 591 Download
  • 22 Web of Science
  • 11 Crossref
Close layer
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
Inkeun Park, Seung Joon Choi, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Yong Ju Shin, Dong Bok Shin
Cancer Res Treat. 2016;48(4):1264-1273.   Published online March 23, 2016
DOI: https://doi.org/10.4143/crt.2015.250
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed.
Results
A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11 to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic disease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.36; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials.

Citations

Citations to this article as recorded by  
  • Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study
    J. Keyl, A. Bucher, F. Jungmann, R. Hosch, A. Ziller, R. Armbruster, P. Malkomes, T.M. Reissig, S. Koitka, I. Tzianopoulos, P. Keyl, K. Kostbade, D. Albers, P. Markus, J. Treckmann, K. Nassenstein, J. Haubold, M. Makowski, M. Forsting, H.A. Baba, S. Kaspe
    ESMO Open.2024; 9(1): 102219.     CrossRef
  • Body composition measures as a determinant of Alpelisib related toxicity
    Eliya Shachar, Ari Raphael, Uriel Katz, Rivka Kessner, Shlomit Strulov Shachar
    Breast Cancer Research and Treatment.2024; 206(2): 369.     CrossRef
  • The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis
    Joshua J. Thompson, Josh McGovern, Campbell S.D. Roxburgh, Joanne Edwards, Ross D. Dolan, Donald C. McMillan
    Critical Reviews in Oncology/Hematology.2024; 199: 104378.     CrossRef
  • Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies
    Antonio Jesús Láinez Ramos-Bossini, Antonio Gámez Martínez, David Luengo Gómez, Francisco Valverde-López, Consolación Melguizo, José Prados
    Cancers.2024; 16(19): 3356.     CrossRef
  • Sarkopenie als unabhängiger Prognosefaktor bei Pankreaskarzinom
    Johanna Mandl, Sebastian Baumer, Bernadette Holtzem, Rainer Theurer, Niels Zorger, Oliver Pech
    Zeitschrift für Gastroenterologie.2023; 61(10): 1365.     CrossRef
  • Association between Body Composition and Peripheral Neurotoxicity in Cancer Patients from North China Taking Nab-Paclitaxel
    Jiayuan Guo, Juan Zhao, Ming Gu, Jixiang Hou, Ting Xu, Ying Jiang, Caihong Jiang, Hui Li, Xiaorong Li, Guang Liu, Lanzhen Zhao, Gaowa Jin, Yongzhi Shi, Ting Liu, Zhenhao Li, Zewei Zhang, Quanfu Li
    Nutrition and Cancer.2023; 75(3): 805.     CrossRef
  • Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer – a Meta-analysis
    Maximilian Thormann, Mattes Hinnerichs, Felix Barajas Ordonez, Sylvia Saalfeld, Aristoteles Perrakis, Roland Croner, Jazan Omari, Maciej Pech, Marina Zamsheva, Hans-Jonas Meyer, Andreas Wienke, Alexey Surov
    Academic Radiology.2023; 30(8): 1552.     CrossRef
  • Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment
    Anne-Laure Couderc, Evelyne Liuu, Pascaline Boudou-Rouquette, Johanne Poisson, Maxime Frelaut, Coline Montégut, Soraya Mebarki, Romain Geiss, Zoé ap Thomas, Aurélien Noret, Monica Pierro, Capucine Baldini, Elena Paillaud, Frédéric Pamoukdjian
    Nutrients.2023; 15(5): 1193.     CrossRef
  • Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study
    Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Natee Ina, Ply Chichareon
    Scientific Reports.2023;[Epub]     CrossRef
  • Prognostic value of pretreatment skeletal muscle index in pancreatic carcinoma patients: A meta-analysis
    Li Yang, Xianghui Liao, Zhong Xie, Haiwen Li
    Medicine.2023; 102(19): e33663.     CrossRef
  • Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients?
    Marco Cefalì, Isabel Scala, Giuliana Pavone, Daniel Helbling, Saskia Hussung, Ralph Fritsch, Cäcilia Reiner, Soleen Stocker, Dieter Koeberle, Marc Kissling, Vito Chianca, Filippo Del Grande, Sara De Dosso, Stefania Rizzo
    Cancers.2023; 15(17): 4398.     CrossRef
  • Sarkopenie als unabhängiger Prognosefaktor bei Pankreaskarzinom
    Johanna Mandl, Sebastian Baumer, Bernadette Holtzem, Rainer Theurer, Niels Zorger, Oliver Pech
    TumorDiagnostik & Therapie.2023; 44(10): 696.     CrossRef
  • Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches
    Chiara Cencioni, Ilaria Trestini, Geny Piro, Emilio Bria, Giampaolo Tortora, Carmine Carbone, Francesco Spallotta
    Nutrients.2022; 14(8): 1542.     CrossRef
  • Sarcopenia
    Hiroyuki Asama, Makoto Ueno, Satoshi Kobayashi, Taito Fukushima, Kuniyuki Kawano, Yusuke Sano, Satoshi Tanaka, Shuhei Nagashima, Manabu Morimoto, Hiromasa Ohira, Shin Maeda
    Pancreas.2022; 51(2): 148.     CrossRef
  • Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study
    Yuichiro Tozuka, Makoto Ueno, Satoshi Kobayashi, Manabu Morimoto, Taito Fukushima, Yusuke Sano, Kuniyuki Kawano, Akane Hanaoka, Shun Tezuka, Hiroyuki Asama, Satoshi Moriya, Soichiro Morinaga, Shinichi Ohkawa, Shin Maeda
    Oncology Letters.2022;[Epub]     CrossRef
  • Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review
    Stefania Rizzo, Isabel Scala, Angela Rodriguez Robayo, Marco Cefalì, Sara De Dosso, Stefano Cappio, Genti Xhepa, Filippo Del Grande
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Dynamic changes in the body composition during chemotherapy for gastrointestinal tumors in the context of active nutrition intervention
    Ting Xu, Zhenhao Li, Hui Li, Jixiang Hou, Jingjing Li, Gaowa Jin, Shaohua Li, Quanfu Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis
    Emanuele Rinninella, Marco Cintoni, Pauline Raoul, Francesca Romana Ponziani, Maurizio Pompili, Carmelo Pozzo, Antonia Strippoli, Emilio Bria, Giampaolo Tortora, Antonio Gasbarrini, Maria Cristina Mele
    Internal and Emergency Medicine.2021; 16(5): 1341.     CrossRef
  • Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study
    In-Ho Kim, Moon Hyung Choi, In Seok Lee, Tae Ho Hong, Myung Ah. Lee
    BMC Cancer.2021;[Epub]     CrossRef
  • The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer
    Tsuyoshi Takeda, Takashi Sasaki, Takafumi Mie, Takaaki Furukawa, Yuto Yamada, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
    Japanese Journal of Clinical Oncology.2021; 51(4): 604.     CrossRef
  • Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model
    Hiroki Sato, Takuma Goto, Akihiro Hayashi, Hidemasa Kawabata, Tetsuhiro Okada, Shuhei Takauji, Junpei Sasajima, Katsuro Enomoto, Mikihiro Fujiya, Kyohei Oyama, Yusuke Ono, Ayumu Sugitani, Yusuke Mizukami, Toshikatsu Okumura
    Pancreatology.2021; 21(5): 892.     CrossRef
  • Current situation, consensus and controversy of perioperative nutrition management in pancreatic surgery: A narrative review
    Jingyong Xu, Junmin Wei
    Journal of Pancreatology.2021; 4(1): 37.     CrossRef
  • Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
    Dong Woo Shin, Minseok Albert Kim, Jong-chan Lee, Jaihwan Kim, Jin-Hyeok Hwang
    BMC Research Notes.2021;[Epub]     CrossRef
  • Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
    Naoto Iwai, Takashi Okuda, Kohei Oka, Junichi Sakagami, Taishi Harada, Tomoya Ohara, Chie Hattori, Masashi Taniguchi, Hiroaki Sakai, Tasuku Hara, Toshifumi Tsuji, Toshiyuki Komaki, Keizo Kagawa, Osamu Dohi, Hiroaki Yasuda, Yoshito Itoh
    Cancers.2021; 13(15): 3860.     CrossRef
  • Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
    Ilaria Trestini, Marco Cintoni, Emanuele Rinninella, Futura Grassi, Salvatore Paiella, Roberto Salvia, Emilio Bria, Carmelo Pozzo, Sergio Alfieri, Antonio Gasbarrini, Giampaolo Tortora, Michele Milella, Maria Cristina Mele
    World Journal of Gastrointestinal Surgery.2021; 13(9): 885.     CrossRef
  • Circulating Immunological Biomarkers
    Fleur van der Sijde, Dana A.M. Mustafa, Eveline E. Vietsch, Peter D. Katsikis, Casper H. J. van Eijck
    Pancreas.2021; 50(7): 933.     CrossRef
  • Influence of sarcopenia in major pancreatic surgery. A systematic review of the literature
    Raquel Aranzazu Latorre Fragua, Alba Manuel Vázquez, Carmen Ramiro Pérez, Roberto de la Plaza Llamas, José Manuel Ramia Ángel
    Gastroenterología y Hepatología.2020; 43(3): 142.     CrossRef
  • Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer
    Fleur van der Sijde, Eveline E. Vietsch, Dana A.M. Mustafa, Yunlei Li, Casper H.J. van Eijck
    Clinica Chimica Acta.2020; 505: 183.     CrossRef
  • Influence of sarcopenia in major pancreatic surgery. A systematic review of the literature
    Raquel Aranzazu Latorre Fragua, Alba Manuel Vázquez, Carmen Ramiro Pérez, Roberto de la Plaza Llamas, José Manuel Ramia Ángel
    Gastroenterología y Hepatología (English Edition).2020; 43(3): 142.     CrossRef
  • The impact of sarcopenia on patients undergoing treatment for pancreatic ductal adenocarcinoma
    Julia R. Amundson, Jelani K. Williams, Andrew J. Benjamin, Hunter D.D. Witmer, Kevin K. Roggin
    Journal of Pancreatology.2020; 3(2): 59.     CrossRef
  • Impact of progressive resistance training on CT quantified muscle and adipose tissue compartments in pancreatic cancer patients
    Raoul Wochner, Dorothea Clauss, Johanna Nattenmüller, Christine Tjaden, Thomas Bruckner, Hans-Ulrich Kauczor, Thilo Hackert, Joachim Wiskemann, Karen Steindorf, Leonardo A. Peyré-Tartaruga
    PLOS ONE.2020; 15(11): e0242785.     CrossRef
  • Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores
    Inhwan Hwang, Jihoon Kang, Hei Nga Natalie Ip, Jae Ho Jeong, Kyu-pyo Kim, Heung-Moon Chang, Changhoon Yoo, Baek-Yeol Ryoo
    Investigational New Drugs.2019; 37(3): 584.     CrossRef
  • Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy
    Yusuke Kurita, Noritoshi Kobayashi, Motohiko Tokuhisa, Ayumu Goto, Kensuke Kubota, Itaru Endo, Atsushi Nakajima, Yasushi Ichikawa
    Pancreatology.2019; 19(1): 127.     CrossRef
  • Significance of the inflammation-based prognostic score in recurrent pancreatic cancer
    Kenji Nakagawa, Masayuki Sho, Takahiro Akahori, Minako Nagai, Kota Nakamura, Tadataka Takagi, Toshihiro Tanaka, Hideyuki Nishiofuku, Chiho Ohbayashi, Kimihiko Kichikawa, Naoya Ikeda
    Pancreatology.2019; 19(5): 722.     CrossRef
  • Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis
    James Bundred, Sivesh K. Kamarajah, Keith J. Roberts
    HPB.2019; 21(12): 1603.     CrossRef
  • Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer
    Sachiyo Onishi, Masahiro Tajika, Tsutomu Tanaka, Yutaka Hirayama, Kazuo Hara, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Yoshitaka Inaba, Takeshi Kodaira, Tetsuya Abe, Kei Muro, Masahito Shimizu, Yasumasa Niwa
    Journal of Clinical Medicine.2019; 8(10): 1647.     CrossRef
  • An update on treatment options for pancreatic adenocarcinoma
    Aurélien Lambert, Lilian Schwarz, Ivan Borbath, Aline Henry, Jean-Luc Van Laethem, David Malka, Michel Ducreux, Thierry Conroy
    Therapeutic Advances in Medical Oncology.2019;[Epub]     CrossRef
  • Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function
    Yeonjung Ha, Daejung Kim, Seungbong Han, Young Eun Chon, Yun Bin Lee, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    Cancer Research and Treatment.2018; 50(3): 843.     CrossRef
  • The Obesity Paradox in Cancer: How Important Is Muscle?
    Elizabeth M. Cespedes Feliciano, Candyce H. Kroenke, Bette J. Caan
    Annual Review of Nutrition.2018; 38(1): 357.     CrossRef
  • Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor
    Sandeep Nadella, Julian Burks, Abdulhameed Al-Sabban, Gloria Inyang, Juan Wang, Robin D. Tucker, Marie E. Zamanis, William Bukowski, Narayan Shivapurkar, Jill P. Smith
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2018; 315(5): G699.     CrossRef
  • Prognostic value of pretreatment serum lactate dehydrogenase level in pancreatic cancer patients
    Jianxin Gan, Wenhu Wang, Zengxi Yang, Jiebin Pan, Liang Zheng, Lanning Yin
    Medicine.2018; 97(46): e13151.     CrossRef
  • 11,737 View
  • 226 Download
  • 41 Web of Science
  • 41 Crossref
Close layer
Dexamethasone Inhibits TGF-β1–Induced Cell Migration by Regulating the ERK and AKT Pathways in Human Colon Cancer Cells Via CYR61
Sanghoon Han, Ngoc Thuy Bui, Manh Tin Ho, Young Mee Kim, Moonjae Cho, Dong Bok Shin
Cancer Res Treat. 2016;48(3):1141-1153.   Published online December 15, 2015
DOI: https://doi.org/10.4143/crt.2015.209
AbstractAbstract PDFPubReaderePub
Purpose
One of the features in cancer development is the migration of cancer cells to form metastatic lesions. CYR61 protein promotes migration and the epithelial-mesenchymal transition in several cancer cell types. Evidence suggests that CYR61 and dexamethasone are relevant to colorectal cancer. However, relationships between them and colorectal cancer are still unclear. Understanding the molecular mechanism of colorectal cancer progression related with CYR61 and dexamethasone, which is widely used for combination chemotherapy, is necessary for improved therapy. Materials and Methods We used colorectal cancer cells, HCT116, co-treated with transforming growth factor β1 (TGF-β1) and dexamethasone to examine the inhibitory migration effect of dexamethasone by migratory assay. Alternatively, both migratory pathways, expression of AKT and ERK, and the target factor CYR61 was also tested by co-treatment with TGF-β1 and dexamethasone.
Results
We report that dexamethasone significantly inhibited TGF-β1–induced cell migration, without affecting cell proliferation. Importantly, we observed that TGF-β1 promoted the epithelial- mesenchymal transition process and that dexamethasone co-treatment abolished this effect. ERK and AKT signaling pathways were found to mediate TGF-β1–induced migration, which was inhibited by dexamethasone. In addition, TGF-β1 treatment induced CYR61 expression whereas dexamethasone reduced it. These observations were compatible with the modulation of migration observed following treatment of HCT116 cells with human recombinant CYR61 and anti-CYR61 antibody. Our results also indicated that TGF-β1 enhanced collagen I and reduced matrix metalloproteinase 1 expression, which was reversed by dexamethasone treatment. Conclusion These findings suggested that dexamethasone inhibits AKT and ERK phosphorylation, leading to decreased CYR61 expression, which in turn blocks TGF-β1–induced migration.

Citations

Citations to this article as recorded by  
  • Dexamethasone improves thymoma-associated myasthenia gravis via the AKT-mTOR pathway
    Yuxin Liu, Si Chen, Yan Wang, Zeyang Zhang, Hui Zhang, Ziyi Wang, Ziyou Tao, Jianyao Wang, Peng Zhang
    Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(2): 817.     CrossRef
  • Global Proteomics Analysis of Lysophosphatidic Acid Signaling in PC-3 Human Prostate Cancer Cells: Role of CCN1
    Pravita Balijepalli, Guihua Yue, Bhagwat Prasad, Kathryn E. Meier
    International Journal of Molecular Sciences.2024; 25(4): 2067.     CrossRef
  • Useful Role of a New Generation of Dexamethasone, Vitamin E and Human Serum Albumin Microparticles in the Prevention of Excitotoxicity Injury in Retinal Ocular Diseases
    Javier Rodríguez Villanueva, Pedro de la Villa, Rocío Herrero-Vanrell, Irene Bravo-Osuna, Manuel Guzmán-Navarro
    Pharmaceutics.2024; 16(3): 406.     CrossRef
  • Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models
    Mireia Tena-Garitaonaindia, María Arredondo-Amador, Cristina Mascaraque, Maitane Asensio, Jose J.G. Marin, Olga Martínez-Augustin, Fermín Sánchez de Medina
    Pharmacological Research.2022; 177: 106056.     CrossRef
  • ROS-responsive dexamethasone micelles normalize the tumor microenvironment enhancing hypericin in cancer photodynamic therapy
    Ruifeng Liang, Ka Hong Wong, Yan Yang, Yourong Duan, Meiwan Chen
    Biomaterials Science.2022; 10(4): 1018.     CrossRef
  • Advantages and drawbacks of dexamethasone in glioblastoma multiforme
    Amir R. Afshari, Mehdi Sanati, Samaneh Aminyavari, Farzaneh Shakeri, Bahram Bibak, Zakieh Keshavarzi, Mohammad Soukhtanloo, Mohammad Jalili-Nik, Mohammad Montazami Sadeghi, Hamid Mollazadeh, Thomas P. Johnston, Amirhossein Sahebkar
    Critical Reviews in Oncology/Hematology.2022; : 103625.     CrossRef
  • Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
    Leila Mohammadi, Bashir Mosayyebi , Mahsa Imani, Mohammad Rahmati
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(13): 2494.     CrossRef
  • Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer
    Mariana Suaya, Gonzalo Manuel Sánchez, Antonella Vila, Analía Amante, María Cotarelo, Mercedes García Carrillo, Matías Blaustein
    Cell Death & Disease.2022;[Epub]     CrossRef
  • Cyr61 from adipose‐derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin αVβ5
    Zhenxing Liang, Huashan Liu, Yunfeng Zhang, Li Xiong, Ziwei Zeng, Xiaowen He, Fengwei Wang, Xianrui Wu, Ping Lan
    Molecular Oncology.2021; 15(12): 3447.     CrossRef
  • Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer
    Alicia M. Hidalgo-Estévez, Konstantinos Stamatakis, Marta Jiménez-Martínez, Ricardo López-Pérez, Manuel Fresno
    Frontiers in Pharmacology.2020;[Epub]     CrossRef

  • Overexpression of lncRNA NLIPMT Inhibits Colorectal Cancer Cell Migration and Invasion by Downregulating TGF-β1


    Yongkang An, Shuangxi Zhang, Jing Zhang, Qing Yin, Haitao Han, Fang Wu, Xiangan Zhang
    Cancer Management and Research.2020; Volume 12: 6045.     CrossRef
  • Transforming Growth Factor Beta 2 Inhibits Growth and Proliferation Potential of Smad4 and p53 Mutated Human Colon Adenocarcinoma Cells
    Ramamoorthi Ganesan, Nageswaran Sivalingam
    Pathology & Oncology Research.2019; 25(2): 819.     CrossRef
  • Downregulation of miR-142-5p promotes tumor metastasis through directly regulating CYR61 expression in gastric cancer
    Jing Yan, Bing Yang, Shuye Lin, Rui Xing, Youyong Lu
    Gastric Cancer.2019; 22(2): 302.     CrossRef
  • Role of the transforming growth factor‐β signaling pathway in the pathogenesis of colorectal cancer
    Atena Soleimani, Mehran Pashirzad, Amir Avan, Gordon A. Ferns, Majid Khazaei, Seyed Mahdi Hassanian
    Journal of Cellular Biochemistry.2019; 120(6): 8899.     CrossRef
  • Tanshinone IIA reverses EGF‑ and TGF‑β1‑mediated epithelial‑mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathway
    Longkai Zhang, Weibin Lin, Xiaodan Chen, Gang Wei, Hailong Zhu, Shangping Xing
    Oncology Letters.2019;[Epub]     CrossRef
  • Dexamethasone and lenvatinib inhibit migration and invasion of non‑small cell lung cancer by regulating EKR/AKT and VEGF signal pathways
    Daye Zhang, Yongxiang Zhang, Zeyuan Cai, Ying Tu, Zhansong Hu
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
    Yusuke Tomita, Kazuhiko Kurozumi, Ji Young Yoo, Kentaro Fujii, Tomotsugu Ichikawa, Yuji Matsumoto, Atsuhito Uneda, Yasuhiko Hattori, Toshihiko Shimizu, Yoshihiro Otani, Tetsuo Oka, Balveen Kaur, Isao Date
    Molecular Cancer Therapeutics.2019; 18(8): 1418.     CrossRef
  • Glucocorticoids indirectly decrease colon cancer cell proliferation and invasion via effects on cancer-associated fibroblasts
    Zuzanna Drebert, Elly De Vlieghere, Jolien Bridelance, Olivier De Wever, Karolien De Bosscher, Marc Bracke, Ilse M. Beck
    Experimental Cell Research.2018; 362(2): 332.     CrossRef
  • UBXN2A enhances CHIP‐mediated proteasomal degradation of oncoprotein mortalin‐2 in cancer cells
    Sanam Sane, Andre Hafner, Rekha Srinivasan, Daniall Masood, John l. Slunecka, Collin J. Noldner, Alex D. Hanson, Taylor Kruisselbrink, Xuejun Wang, Yiyang Wang, Jun Yin, Khosrow Rezvani
    Molecular Oncology.2018; 12(10): 1753.     CrossRef
  • Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer
    Xinpeng Li, Naxin Yuan, Lingdan Lin, Lixia Yin, Yiqing Qu
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy
    Qi Zhang, Bo Zhu, Yongsheng Li
    Frontiers in Immunology.2017;[Epub]     CrossRef
  • Crosstalk between Smad2/3 and specific isoforms of ERK in TGF‐β1‐induced TIMP‐3 expression in rat chondrocytes
    Yanhui Zhu, Jianhua Gu, Tong Zhu, Chen Jin, Xiaopeng Hu, Xiang Wang
    Journal of Cellular and Molecular Medicine.2017; 21(9): 1781.     CrossRef
  • Ginsenoside Rg1 Attenuates Cigarette Smoke-Induced Pulmonary Epithelial-Mesenchymal Transition via Inhibition of the TGF-β1/Smad Pathway
    Sibin Guan, Weiguo Xu, Fengfeng Han, Wen Gu, Lin Song, Wenjing Ye, Qian Liu, Xuejun Guo
    BioMed Research International.2017; 2017: 1.     CrossRef
  • TGF-β1/PTEN/PI3K signaling plays a critical role in the anti-proliferation effect of tetrandrine in human colon cancer cells
    Qian-Zhao Chen, Yang Li, Ying Shao, Yu-Hua Zeng, Wen-Yan Ren, Rong-Xing Liu, Lin-Yun Zhou, Xue-Lian Hu, Ming Huang, Fang He, Wen-Juan Sun, Ke Wu, Bai-Cheng He
    International Journal of Oncology.2017; 50(3): 1011.     CrossRef
  • C1QBP is upregulated in colon cancer and binds to apolipoprotein A-I
    Kun Kim, Min-Jeong Kim, Kyung-Hee Kim, Sun-A Ahn, Jong Heon Kim, Jae Youl Cho, Seung-Gu Yeo
    Experimental and Therapeutic Medicine.2017; 13(5): 2493.     CrossRef
  • Chimeric antibody targeting SRPK-1 in the treatment of non-small cell lung cancer by inhibiting growth, migration and invasion
    Fan Wu, Jie Li, Xin Du, Weisan Zhang, Ping Lei, Qiang Zhang
    Molecular Medicine Reports.2017; 16(2): 2121.     CrossRef
  • MicroRNA target for MACC1 and CYR61 to inhibit tumor growth in mice with colorectal cancer
    Guiqi Wang, Jingfeng Gu, Yingchao Gao
    Tumor Biology.2016; 37(10): 13983.     CrossRef
  • Systematic review of the old and new concepts in the epithelial-mesenchymal transition of colorectal cancer
    Simona Gurzu, Camelia Silveanu, Annamaria Fetyko, Vlad Butiurca, Zsolt Kovacs, Ioan Jung
    World Journal of Gastroenterology.2016; 22(30): 6764.     CrossRef
  • 16,102 View
  • 251 Download
  • 37 Web of Science
  • 28 Crossref
Close layer
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Young Saing Kim, Eun Kyung Cho, Hyun Sun Woo, Junshik Hong, Hee Kyung Ahn, Inkeun Park, Sun Jin Sym, Sun Young Kyung, Shin Myung Kang, Jeong-Woong Park, Sung Hwan Jeong, Jinny Park, Jae Hoon Lee, Dong Bok Shin
Cancer Res Treat. 2016;48(1):80-87.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.307
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Materials and Methods Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m² of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months.
Results
A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFRmutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no significant differences (RR: 39% vs. 9%, p=0.07; median PFS: 6.6 months vs. 3.1 months, p=0.45; median OS: 29.6 months vs. 12.9 months, p=0.62). Toxicities were mild in both treatment arms. Frequently reported toxicities were anemia and fatigue for pemetrexed, and skin rash and anorexia for gefitinib. Conclusion Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. However, pemetrexed is considered more effective than gefitinib for EGFR wild-type patients.

Citations

Citations to this article as recorded by  
  • A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer
    Himani Aggarwal, Kerigo Ndirangu, Katherine B Winfree, Catherine Elizabeth Muehlenbein, Emily Zhu, Vanita Tongbram, Howard Thom
    Journal of Comparative Effectiveness Research.2023;[Epub]     CrossRef
  • Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
    Yi Zhao, Bo Cheng, Zisheng Chen, Jianfu Li, Hengrui Liang, Ying Chen, Feng Zhu, Caichen Li, Ke Xu, Shan Xiong, Weixiang Lu, Zhuxing Chen, Ran Zhong, Shen Zhao, Zhanhong Xie, Jun Liu, Wenhua Liang, Jianxing He
    Critical Reviews in Oncology/Hematology.2021; 160: 103305.     CrossRef
  • Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis
    Zhihao Zhang, Xiyong Wang, Huaiqing Xiao, Dongqiang Wu, Dongliang Zhang, Qun Yu, Linna Yuan, Tao Huang
    Computational and Mathematical Methods in Medicine.2021; 2021: 1.     CrossRef
  • A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
    Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li
    Medicine.2020; 99(29): e21170.     CrossRef
  • Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
    Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
    Pteridines.2019; 30(1): 171.     CrossRef
  • Gefitinib for advanced non-small cell lung cancer
    Esther HA Sim, Ian A Yang, Richard Wood-Baker, Rayleen V Bowman, Kwun M Fong
    Cochrane Database of Systematic Reviews.2018;[Epub]     CrossRef
  • Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
    Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino
    Lung Cancer.2018; 123: 60.     CrossRef
  • Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
    Jens Köhler
    Frontiers in Medicine.2017;[Epub]     CrossRef
  • 13,251 View
  • 126 Download
  • 15 Web of Science
  • 8 Crossref
Close layer
Case Reports
Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
Hyun Sun Woo, Kyoung Hwa Lee, Phill Hoon Yoon, Su Ji Kim, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Dong Bok Shin, Sun Jin Sym
Cancer Res Treat. 2015;47(4):949-953.   Published online October 28, 2014
DOI: https://doi.org/10.4143/crt.2014.052
AbstractAbstract PDFPubReaderePub
Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immunemediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.

Citations

Citations to this article as recorded by  
  • Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies
    Ju Li, Wanqing Wang, Kaipeng Jiang, Jiuwei Cui, Chang Wang, Tingting Liang, Yizhuo Wang, Shuhan Liu, Wenshuo Zhou
    Journal of Gastrointestinal Cancer.2024; 55(3): 1144.     CrossRef
  • Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report
    Khin Pyai, David I LeRoy, Joseph Attallah, Hosam Hakim, Zyad Kafri
    Cureus.2024;[Epub]     CrossRef
  • The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients
    Marek Kos, Piotr Tomaka, Paulina Mertowska, Sebastian Mertowski, Julia Wojnicka, Anna Błażewicz, Ewelina Grywalska, Krzysztof Bojarski
    Journal of Clinical Medicine.2024; 13(22): 6738.     CrossRef
  • Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
    You Zou, Shuang Liu, Jianhong Wu, Zhen Sun
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • A case of idiosyncratic liver injury after oxaliplatin‐induced thrombocytopenia
    Shinji Honda, Masayuki Tsujimoto, Tetsuya Minegaki, Tomohiko Mori, Junji Muraoka, Kohshi Nishiguchi
    Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 373.     CrossRef
  • Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents
    Benjamin K. Gersten, Tracy S. Fitzgerald, Katharine A. Fernandez, Lisa L. Cunningham
    Journal of the Association for Research in Otolaryngology.2020; 21(4): 303.     CrossRef
  • Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms
    Haider Ghazanfar, Iqra Nawaz, Nisha Ali
    Cureus.2020;[Epub]     CrossRef
  • Oxaliplatin Treatment Alters Systemic Immune Responses
    Vanesa Stojanovska, Monica Prakash, Rachel McQuade, Sarah Fraser, Vasso Apostolopoulos, Samy Sakkal, Kulmira Nurgali
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study
    Katia Bencardino, Gianluca Mauri, Alessio Amatu, Federica Tosi, Erica Bonazzina, Laura Palmeri, Marialuisa Querques, Federica Ravera, Alberto Menegotto, Elisa Boiani, Andrea Sartore-Bianchi, Salvatore Siena
    Clinical Colorectal Cancer.2016; 15(3): 213.     CrossRef
  • 12,696 View
  • 116 Download
  • 10 Web of Science
  • 9 Crossref
Close layer
Recurrent and Metastatic Trichilemmal Carcinoma of the Skin Over the Thigh: A Case Report
Hyon Seung Yi, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Seung-Yeon Ha, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2010;42(3):176-179.   Published online September 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.3.176
AbstractAbstract PDFPubReaderePub

Trichilemmal carcinoma (TC) is an uncommon cutaneous neoplasm that develops from the external root sheath of the hair follicle. It is considered to be a low-grade carcinoma with low metastatic potential. Local recurrence and metastasis are rare after surgical excision. We report here on a case of metastatic TC in the skin over the thigh, and this tumor was treated with cisplatin and cyclophosphamide combination chemotherapy.

Citations

Citations to this article as recorded by  
  • Trichilemmal carcinoma metastatic to parotid gland: First report of fine needle aspiration cytology features
    Priya Jayakumar, Aanchal Kakkar, Sudheer Arava, Supriya Mallick
    Diagnostic Cytopathology.2024;[Epub]     CrossRef
  • Successful treatment of trichilemmal carcinoma with distant metastasis using pembrolizumab: a case report and review
    Lei Liu, Tengfei Long, Nannan Wei, Hongyan Zhang, Chaoliang Tang, Jin Gao
    Immunotherapy.2024; 16(10): 659.     CrossRef
  • A Rare Case of Trichilemmal Carcinoma of the Scalp
    Raymart Macasaet, FNU Arty, Janelle du Toit, Sai Gaddameedi, Shazia M Shah
    Cureus.2024;[Epub]     CrossRef
  • Malignant pilar cyst in a young woman: Case report and literature review
    Ali Ibrahim Ali Hegy, Amina Ibrahim El-yakub, Yaser Taha Sidahmed
    International Journal of Case Reports and Images.2024; 15(1): 89.     CrossRef
  • A Rare Case Of Trichilemmal Carcinoma In A Sun-unexposed Area
    Alemwosen Alem, Alazar Aregawi, Teketel Geremew
    Journal of Global Surgery (ONE).2024;[Epub]     CrossRef
  • Trichilemmal carcinoma treated by excision combined with photodynamic therapy: a case report and review of literature
    Lingyu Qidiao, Yilin Liu, Danni Hu, Xingchi Tao, Chunli Yao
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Systematic analysis and case series of the diagnosis and management of trichilemmal carcinoma
    Jiachen Sun, Lihua Zhang, Minglu Xiao, Shiyi Li, Runkai Chen, Ying Li, Yuguang Yang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • When to sweat: A history of chemotherapy in malignant sweat gland tumors. A unique case report and literature review
    J. Matthiesen, R. Chiu, T. T. Do, S. Bamdad, J. Lee, S. K. Peng
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Recurrent trichilemmal carcinoma of the periorbital region treated with IMRT radiotherapy: A case report and a review of literature
    Shan Gao, Qin Xu, Yanli Lan, Lang He
    Medicine.2023; 102(24): e34038.     CrossRef
  • Malignant proliferating trichilemmal tumor in abdominal wall: Report of a rare case at an uncommon site with literature review
    Mahdokht Azizi, Mazaher Ramezani
    Clinical Case Reports.2022;[Epub]     CrossRef
  • Trichilemmal Carcinoma of the Scalp in a Young Female: A Case Report
    Qiuyu Jia, Yunyan Yuan, Dandan Mao, Guangdong Wen, Xue Chen
    Clinical, Cosmetic and Investigational Dermatology.2022; Volume 15: 139.     CrossRef
  • Current Treatment Options for Cutaneous Adnexal Malignancies
    Hiroyuki Goto
    Current Treatment Options in Oncology.2022; 23(5): 736.     CrossRef
  • Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation
    Iga Płachta, Marcin Kleibert, Anna M. Czarnecka, Mateusz Spałek, Anna Szumera-Ciećkiewicz, Piotr Rutkowski
    International Journal of Molecular Sciences.2021; 22(9): 4759.     CrossRef
  • Huge Trichilemmal Carcinoma With Metastasis Presenting With Two Distinct Histological Morphologies: A Case Report
    Yao Xie, Lin Wang, Tingting Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Trichilemmal carcinoma in a patient with squamous cell skin cancer
    V. A. Smolyannikova, M. A. Nefedova
    Arkhiv patologii.2019; 81(1): 31.     CrossRef
  • Locally aggressive trichilemmal carcinoma
    Ana María Maya-Rico, Catalina Jaramillo-Pulgarín, Ángela Londoño-García, Bibiana Peña-Zúñiga
    Anais Brasileiros de Dermatologia.2018; 93(4): 579.     CrossRef
  • Cells to Surgery Quiz: April 2018
    Ali Rajabi-Estarabadi, Sofia Iglesia, Jacob W. Griggs, Pooja Gurnani, Samuel C. Smith, Cassandra IF. Collins, Keyvan Nouri
    Journal of Investigative Dermatology.2018; 138(4): e37.     CrossRef
  • Adnexal Carcinomas Treated With Mohs Micrographic Surgery: A Comprehensive Review
    Stanislav N. Tolkachjov
    Dermatologic Surgery.2017; 43(10): 1199.     CrossRef
  • Malignant hair follicle tumors of the periorbital region: A review of literature and suggestion of a management guideline
    Paul Ikgan Sia, Edwin Figueira, Alexandra Allende, Dinesh Selva
    Orbit.2016; 35(3): 144.     CrossRef
  • Metastatic trichilemmal carcinoma in a patient with breast cancer
    Chrysis Sofianos, Nkhensani Y Chauke, Alexandra Grubnik
    BMJ Case Reports.2016; : bcr2016217661.     CrossRef
  • A Case of Trichilemmal Carcinoma With Distant Metastases in a Kidney Transplantation Patient
    K. Hiramatsu, K. Sasaki, M. Matsuda, M. Hashimoto, T. Eguchi, S. Tomikawa, T. Fujii, G. Watanabe
    Transplantation Proceedings.2015; 47(1): 155.     CrossRef
  • Challenges in the diagnosis of cutaneous adnexal tumours
    Richard Danialan, Kudakwashe Mutyambizi, Phyu P Aung, Victor G Prieto, Doina Ivan
    Journal of Clinical Pathology.2015; 68(12): 992.     CrossRef
  • Survival study and clinicopathological evaluation of trichilemmal carcinoma
    SHI-MIN ZHUANG, GE-HUA ZHANG, WEN-KUAN CHEN, SHU-WEI CHEN, LI-PING WANG, HUAN LI, MING SONG
    Molecular and Clinical Oncology.2013; 1(3): 499.     CrossRef
  • Unusual Invasion of Trichilemmal Umors: Two Case Reports
    Mehtap Karamese, Ahmet Akatekin, Malik Abaci, Zekeriya Tosun, Mustafa Keskin
    Modern Plastic Surgery.2012; 02(03): 54.     CrossRef
  • 9,910 View
  • 71 Download
  • 24 Crossref
Close layer
Original Articles
Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer
Young Saing Kim, Junshik Hong, Sun Jin Sym, Se Hoon Park, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Dong Bok Shin
Cancer Res Treat. 2010;42(1):24-29.   Published online March 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.1.24
AbstractAbstract PDFPubReaderePub
Purpose

This study was designed to determine the efficacy and safety of FOLFOX-4 chemotherapy as a salvage treatment for patients with advanced gastric cancer (AGC).

Materials and Methods

The AGC patients with an ECOG performance status of 0~1 and progressive disease after prior treatments were registered onto this phase II trial. The patients received oxaliplatin (85 mg/m2 on day 1), leucovorin (200 mg/m2 on days 1 and 2) and 5-fluorouracil (400 mg/m2 as a bolus and 600 mg/m2 as a 22-hour infusion on days 1 and 2) every 2 weeks.

Results

For the 42 treated patients, a total of 228 chemotherapy cycles (median: 5, range: 1~12) were administered. Twenty-nine patients (69%) received FOLFOX-4 chemotherapy as a third-(50%) or fourth-line (19%) treatment. On the intent-to-treat analysis, 9 patients (21%) achieved a partial response, which was maintained for 4.6 months. The median progression-free survival and overall survival were 3.0 months and 6.2 months, respectively. The frequently encountered toxicities were neutropenia and gastrointestinal side effects, including anorexia. Although there was one possible treatment-related death, the toxicity profiles were generally predictable and manageable.

Conclusion

Salvage chemotherapy with FOLFOX-4 is an effective and tolerable regimen for those heavily pretreated AGC patients who have a good performance status.

Citations

Citations to this article as recorded by  
  • Strategic Developments in Polymer-Functionalized Liposomes for Targeted Colon Cancer Therapy: An Updated Review of Clinical Trial Data and Future Horizons
    Satyam Sharma, Moitrai Chakraborty, Dharmendra Yadav, Aniket Dhullap, Raghuraj Singh, Rahul Kumar Verma, Sankha Bhattacharya, Sanjiv Singh
    Biomacromolecules.2024; 25(9): 5650.     CrossRef
  • Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma
    Domenico D’Arca, Leda Severi, Stefania Ferrari, Luca Dozza, Gaetano Marverti, Fulvio Magni, Clizia Chinello, Lisa Pagani, Lorenzo Tagliazucchi, Marco Villani, Gianluca d’Addese, Isabella Piga, Vincenza Conteduca, Lorena Rossi, Giorgia Gurioli, Ugo De Gior
    Cancers.2023; 15(2): 412.     CrossRef
  • Melatonin as an adjuvant treatment modality with doxorubicin [Biochimie 200 (2022) 1–7]
    Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
    Biochimie.2022; 200: 1.     CrossRef
  • Melatonin as an adjuvant treatment modality with doxorubicin
    Parisa Maleki Dana, Fatemeh Sadoughi, Russel J. Reiter, Sotoudeh Mohammadi, Zahra Heidar, Masoumeh Mirzamoradi, Zatollah Asemi
    Biochimie.2022; 202: 49.     CrossRef
  • A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)
    Hirokazu Shoji, Daisuke Takahari, Hiroki Hara, Kengo Nagashima, Jun Adachi, Narikazu Boku
    Future Science OA.2021;[Epub]     CrossRef
  • Design principles of drug combinations for chemotherapy
    Debra Wu, Anusha Pusuluri, Douglas Vogus, Vinu Krishnan, C. Wyatt Shields, Jayoung Kim, Amaya Razmi, Samir Mitragotri
    Journal of Controlled Release.2020; 323: 36.     CrossRef
  • A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies
    Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Chihiro Kondoh, Isao Oze, Kyoko Kato, Toshiki Masuishi, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
    Advances in Therapy.2020; 37(6): 2853.     CrossRef
  • The role of curcumin/curcuminoids during gastric cancer chemotherapy: A systematic review of non-clinical study
    Masoud Najafi, Keywan Mortezaee, Mahban Rahimifard, Bagher Farhood, Hamed Haghi-Aminjan
    Life Sciences.2020; 257: 118051.     CrossRef
  • Potential therapeutic effects of curcumin in gastric cancer
    Nastaran Barati, Amir A. Momtazi‐Borojeni, Muhammed Majeed, Amirhossein Sahebkar
    Journal of Cellular Physiology.2019; 234(3): 2317.     CrossRef
  • Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer
    Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee
    Cancer Research and Treatment.2019; 51(1): 223.     CrossRef
  • Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
    Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
    Gastric Cancer.2018; 21(6): 1050.     CrossRef
  • Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
    In Sil Choi, Mihong Choi, Ju Hyun Lee, Jee Hyun Kim, Koung Jin Suh, Ji Yun Lee, Beodeul Kang, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
    PLOS ONE.2018; 13(6): e0198544.     CrossRef
  • A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
    In Sil Choi, Jee Hyun Kim, Ju Hyun Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se-Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee, Ju-Seog Lee
    PLOS ONE.2018; 13(10): e0205853.     CrossRef
  • Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
    Vincenza Conteduca, Giorgia Gurioli, Lorena Rossi, Emanuela Scarpi, Cristian Lolli, Giuseppe Schepisi, Alberto Farolfi, Delia De Lisi, Valentina Gallà, Salvatore Luca Burgio, Cecilia Menna, Andrea Amadori, Lorena Losi, Dino Amadori, Maria Paola Costi, Ugo
    BMC Cancer.2018;[Epub]     CrossRef
  • Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX
    Sung Yong Oh, Aesun Shin, Seong-Geun Kim, Jung-Ah Hwang, Seung Hyun Hong, Yeon-Su Lee, Hyuk-Chan Kwon
    Oncotarget.2016; 7(21): 31204.     CrossRef
  • Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
    Tumor Biology.2014; 35(4): 2941.     CrossRef
  • Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
    Suee Lee, Sung Yong Oh, Sung Hyun Kim, Ji Hyun Lee, Min Chan Kim, Ki Han Kim, Hyo-Jin Kim
    BMC Cancer.2013;[Epub]     CrossRef
  • The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer
    Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Jung-Ah Hwang, Seung Hyun Hong, Christian A Graves, Kevin Camphausen, Hyo-Jin Kim, Yeon-Su Lee
    BMC Cancer.2013;[Epub]     CrossRef
  • Prognostic Significance of Serum Levels of Vascular Endothelial Growth Factor and Insulin-Like Growth Factor-1 in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy
    Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Christian A. Graves, Kevin Camphausen, Hyo-Jin Kim
    Chemotherapy.2012; 58(6): 426.     CrossRef
  • Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
    K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
    Japanese Journal of Clinical Oncology.2012; 42(8): 686.     CrossRef
  • The clinical research of elemene emulsion combined with FOLFOX4 regimen in the treatment of advanced gastric carcinoma
    Yanzhi Bi, Dongxiang Zeng, Yang Ling
    The Chinese-German Journal of Clinical Oncology.2012; 11(6): 336.     CrossRef
  • Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor
    Jun Chul Park, Jae-Hoon Lee, Kungseok Cheoi, Hyunsoo Chung, Mi Jin Yun, Hyuk Lee, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee
    European Journal of Nuclear Medicine and Molecular Imaging.2012; 39(7): 1107.     CrossRef
  • Comparison of the Toxicities and Efficacies of the Combination Chemotherapy Regimens in Advanced Gastric Cancer Patients Who Achieved Complete Response after Chemotherapy
    Yun Jeung Kim, Pyung Gohn Goh, Eui Sik Kim, Su Youn Lee, Hee Seok Moon, Eaum Seok Lee, Jae Kyu Sung, Seok Hyun Kim, Byung Seok Lee, Hyun Yong Jeong
    The Korean Journal of Gastroenterology.2011; 58(6): 311.     CrossRef
  • Targeted Therapies for Gastric Cancer
    Jaclyn Yoong, Michael Michael, Trevor Leong
    Drugs.2011; 71(11): 1367.     CrossRef
  • Evolving Standards of Care in Advanced Gastric Cancer
    Jean-Emmanuel Kurtz, Patrick Dufour
    Future Oncology.2011; 7(12): 1441.     CrossRef
  • 12,200 View
  • 122 Download
  • 25 Crossref
Close layer
A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer
Se Hoon Park, Soo Yeon Jeon, Kwang Il Ko, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Ki Lee, Min Chung
Cancer Res Treat. 2006;38(3):121-125.   Published online June 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.3.121
AbstractAbstract PDFPubReaderePub
Purpose

Irinotecan, in combination with leucovorin/5-fluorouracil (FU) or with cisplatin, is known to be active for treating advanced gastric cancer (AGC). This pilot study evaluated a novel three-drug combination of irinotecan, leucovorin/FU and cisplatin as a first-line treatment of AGC. The primary endpoint was to assess the feasibility in anticipation of conducting a larger phase II study.

Materials and Methods

Chemotherapy-naive AGC patients received irinotecan 150 mg/m2 on day 1, and leucovorin 200 mg/m2 and a 22-h infusion of FU 1000 mg/m2 on days 1 and 2. Cisplatin 30 mg/m2 was administered on day 2. Treatment was repeated every 2 weeks until disease progression or unacceptable toxicity.

Results

Of the 17 eligible patients, two patients had an ECOG performance status of 2 and their median age was 48 years (range: 31 to 69). A total of 117 chemotherapy cycles were delivered (median: 6, range: 1 to 12). The causes of treatment discontinuation were disease progression in 9 patients (53%), refusal (35%) and toxicity (12%). Although grade 3 or 4 neutropenia (41% of patients) was the major toxicity that required dose adjustments, only one episode of febrile neutropenia occurred. Grade 3 or 4 nausea and vomiting, diarrhea and fatigue were observed in 35%, 35% and 29% of patients, respectively. None of the patients died of toxicity during treatment. Of the 16 patients who were evaluable for response, 7 (44%) experienced a partial response.

Conclusion

This novel multi-drug combination was tolerated well in patients with AGC. Based on the encouraging efficacy and tolerability, a randomized phase II study is ongoing in this disease setting.

Citations

Citations to this article as recorded by  
  • Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer
    S.H. Park, E. Nam, J. Park, E.K. Cho, D.B. Shin, J.H. Lee, W.K. Lee, M. Chung, S.I. Lee
    Annals of Oncology.2008; 19(4): 729.     CrossRef
  • 9,741 View
  • 60 Download
  • 1 Crossref
Close layer
A Phase II Study of Weekly Paclitaxel, Cisplatin and Concurrent Radiation Therapy for Locally-Advanced Unresectable Non-Small Cell Lung Cancer: Early Closure due to Lack of Efficacy
Se Hoon Park, Mi Kyung Kim, Sun Young Kyung, Young-Hee Lim, Chang Hyeok An, Jeong Woong Park, Seong Hwan Jeong, Jae Woong Lee, Kyu Chan Lee, Eun Kyung Cho, Soo Mee Bang, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2004;36(5):293-297.   Published online October 31, 2004
DOI: https://doi.org/10.4143/crt.2004.36.5.293
AbstractAbstract PDFPubReaderePub
Purpose

In this phase II study, the efficacy and safety of weekly paclitaxel concomitant with cisplatin and thoracic radiotherapy (TRT) was evaluated in patients with locally-advanced unresectable non-small cell lung cancer (NSCLC).

Materials and Methods

Patients with stage III NSCLC (without pleural effusion or cervical lymphadenopathy) received TRT (63 Gy in 35 fractions over 7 weeks) with concurrent weekly cisplatin 20 mg/m2 and paclitaxel 40 mg/m2/week infused over 3 hours. In patients without evidence of disease progression, the administration of a further 2 cycles of consolidation chemotherapy, consisting of paclitaxel 175 mg/m2 and cisplatin 75 mg/m2, were planned after completion of the TRT.

Results

Between Feb 2000 and Dec 2002, 20 patients were entered into the study; 13 completed all 7 weeks of treatment (median 7.6 weeks; range 3.3 to 9.4). Seven out of 16 (43.8%) objective responses were observed, with 15 (75%) patients experiencing at least one episode of grade 3/4 toxicity. The main toxicities were moderate to severe neutropenia and gastrointestinal toxicity.

Conclusion

The unsatisfactory response rate and the high incidence of grade 3/4 hematologic and non-hematologic toxicities, including 7 early discontinuations of treatment and exceeding the study stopping rules, prompted the early closure of the study. In view of the activity observed, the protocol was amended to protracted continuous infusion paclitaxel, cisplatin and concurrent TRT.

  • 8,425 View
  • 53 Download
Close layer
A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer
Jung Ae Lee, Keun Seok Lee, Jin Seok Ahn, Jae Ho Byun, Hun Ho Song, Dae Young Zang, Young Iee Park, Young Suk Park, Eun Kyung Mo, Dong Kyu Kim, Myung Goo Lee, In Gyu Hyun, Ki Suck Jung, Soo Mee Bang, Gye Young Park, Jeong Woong Park, Eun Kyung Cho, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2003;35(3):239-244.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.239
AbstractAbstract PDF
PURPOSE
Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein. MATERIALS AND METHODS: Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2. RESULTS: The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed.
CONCLUSION
The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.

Citations

Citations to this article as recorded by  
  • The Efficacy and Safety of Padexol® (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer
    Hoon-Kyo Kim, Jun Suk Kim, Hun Mo Ryoo, Dong Gun Shin, Byoung Young Shim, Kyong Hwa Park, Sung Hwa Bae, Chi Hong Kim
    Cancer Research and Treatment.2006; 38(2): 66.     CrossRef
  • 4,846 View
  • 32 Download
  • 1 Crossref
Close layer
Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil, and Leucovorin in 5-Fluorouracil-Pretreated Patients with Metastatic Colorectal Cancer
Soo Mee Bang, Eun Kyung Cho, Jae Hwan Oh, Heung Moon Chang, Jin Seok Ahn, Jung Ae Lee, Young Iee Park, Myung Jue Ahn, Young Suk Park, Dong Bok Shin, Jae Hoon Lee
Cancer Res Treat. 2001;33(5):414-419.   Published online October 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.5.414
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer who previously treated with 5-FU-based chemotherapy.
MATERIALS AND METHODS
Between April 1999 and January 2001, thirty-two patients were enrolled in this study. Oxaliplatin 130 mg/m2 was given intravenously (IV) on day 1 as was 5-FU 500 mg/m2 IV followed by continuous infusion of 5-FU 3,000 mg/m2 and LV 100 mg/m2 for 48 hours administered every 3 weeks. Six patients had received 5-FU as an adjuvant setting and 26 patients as a palliative regimen.
RESULTS
The median age of the patients was 50 years (range; 19-69) and the dominant sites of metastasis were the liver, lung or both in 9, 5 and 2 patients respectively. In 30 evaluable patients, the overall response rate was 27% including 1 complete response and 7 partial responses. The median response duration was 28 weeks (95% confidence interval; 22~34 weeks) and the median progression free survival of all patients was 24 weeks (95% confidence interval; 15~33 weeks). A median 5 cycles (range; 2~9) and total 155 cycles were performed in 32 patients. 150 cycles were evaluable for toxicity. The most common hematologic toxicity was grade 1~2 anemia in 78 cycles (52%). Leukopenia (39%) and thrombocytopenia (23%) were fully reversible. The most common non-hematologic toxicity was nausea/vomiting (43/30%) followed by diarrhea (23%), hepatotoxicity (21%) and neurotoxicity (21%). One patient ceased therapy due to grade 4 diarrhea. No other severe toxicity interrupted this treatment.
CONCLUSION
Oxaliplatin, 5-FU and LV in combination showed significant activity in previously treated metastatic colorectal cancer with favorable toxicity.

Citations

Citations to this article as recorded by  
  • Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer
    Byoung Yong Shim, Kang Moon Lee, Hyeon-Min Cho, Hyun Jin Kim, Hong Joo Cho, Jinmo Yang, Jun-Gi Kim, Hoon-Kyo Kim
    Cancer Research and Treatment.2005; 37(4): 212.     CrossRef
  • 5,433 View
  • 27 Download
  • 1 Crossref
Close layer
High Dose Chemotherapy with Ifosfamide, Carboplatin, and Etoposide Followed by Autologous Stem Cell Transplantation in Breast Cancer
Soo Mee Bang, Se Hoon Lee, Eun Kyung Cho, Jung Ae Lee, Young Suk Park, Dong Bok Shin, Jae Hoon Lee, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim
J Korean Cancer Assoc. 2000;32(6):1059-1066.
AbstractAbstract PDF
PURPOSE
To establish the feasibility of high dose ifosfamide, carboplatin, and etoposide (ICE) chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with high-risk or metastatic breast cancer.
MATERIALS AND METHODS
High-risk breast cancer is defined as 10 or more involved axillary lymph nodes (n=3) or stage III (n=2). Patients with metastatic cancer have relapsed diseases after curative resection (n=10) or initially metastatic lesion (n=1). Colony stimulating factor with either cyclophosphamide or combination chemotherapy was administered to mobilize the stem cells. High dose chemotherapy consisted of ifosfamide 16 g/m2, carboplatin 1.8 g/m2, and etoposide 0.75 g/m2 (dose I) and later modified to ifosfamide 12 g/m2, carboplatin 1.35 g/m2, and etoposide 1.2 g/m2 (dose II).
RESULTS
The median duration of grunulocyte nadir (<500/ microliter) was 11 (10~17) days and platelet transfusion dependency (<20,000/ microliter) was 11 (7~53) days in 14 patients who achieved engraftment. One out of 5 patients with high-risk breast cancer relapsed after high dose therapy. Two patients remain disease-free at 18th and 40th months. Two among the 4 patients treated with dose I died due to treatment-related complications. The responses of metastatic diseases to ICE chemotherapy were 1 continuing CR, 1 CR, 1 PR, 4 SD and 3 PD in 10 evaluable patients.
CONCLUSION
High dose ICE chemotherapy, especially dose II and ASCT were feasible in high-risk or metastatic breast cancer.
  • 3,407 View
  • 32 Download
Close layer
A Phase 2 Study with Vinorelbine and Ifosfamide in the Inoperable Non - small Cell Lung Cancer
Moon Hee Lee, Young Jin Yoo, Soo Mi Bang, Gyung Hae Joung, Hyo Jin Kim, Dong Bok Shin, Soon Nam Lee, Seong Rok Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
J Korean Cancer Assoc. 1999;31(5):972-978.
AbstractAbstract PDF
PURPOSE
A phase II study of vinorelbine and ifosfamide combination chemotherapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC) was conducted to assess response rate, response duration, and toxicites.
MATERIALS AND METHODS
Patients with advanced NSCLC who had no prior systemic chemotherapy were eligible. They have no central nervous system metastasis and recurrent or progressive disease after surgery or radiotherapy. Each cycle consisted of vinorelbine 25 mg/m' i.v. days 1 & 8, and ifosfamide 2 g/m i.v. days 1, 2 & 3 with Mesna and treatments were repeated every 21 days.
RESULTS
Forty patients with advanced or recurrent NSCLC were treated at multi center between March, 1997 and March, 1998. Six patients were not evaluable because five patients refused therapy after the first course and one patient was protocol violation. Of 34 evaluable patients, objective responses were seen in 11 (32.4%) patients (CR 0%, PR 32.4%). The median duration of response was 16.4 weeks. The median overall survival was 9.5 months. The toicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION
We concluded that combination regimen of vinorelbine and ifosfamide was effective and tolerable in the treatment of advanced non-small cell lung cancer.
  • 2,476 View
  • 16 Download
Close layer
Four Cases of Typhlitis, Developed in Neutropenic State and Treated with Medical Conservative Management
Pill Woon Kim, Hyeon Gyoo Ji, Hyun Sik Jeong, Chan Il Moon, Dong Kyeong Yang, Seung Won Lee, Yon Sil Jung, Ji Ho Choi, Gui Hyun Nam, Jae Hoon Lee, Dong Bok Shin
J Korean Cancer Assoc. 1997;29(5):906-913.
AbstractAbstract PDF
Typhlitis is a life threatening necrotizing enterocolitis of the cecum, ascending colon and terminal ileum seen in severely neutropenic patients, however its pathogenesis is not identified up to this time.The incidence of typhlitis in leukemic patient is 10~12%, estimated by postmortem examination, and 46% in induction chemotherapy of leukemia. Recently, entity incidence is more high due to increasing challenges to high dose chemotherapy in solid tumors.We experienced four cases of typhlitis, one was developed in the circumstance of neutropenia induced by induction chemotherapy for acute myelocytic leukemia and others in neutropnia due to primary diseases without chemotherapy, ig, chronic myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome.All cases were treated with high dose broad spectrum antibiotics in early phase of disease and its outcome was good, so that, early diagnosis of typhlitis is essential, then prompt treatment with high dose antibiotics and intravenous fluid before onset of transmural necrosis is associated with lower morbidity and mortality than surgical resection.
  • 2,805 View
  • 23 Download
Close layer
A Case of Metastatic Epididymal and the Other Metastatic Testicular Carcinoma from Sigmoid Carcinoma
Yon Sil Jung, Dong Kyeong Yang, Pill Woon Kim, Chan Il Moon, Seung Won Lee, Hyeon Gyoo Ji, Ji Ho Choi, Jae Hun Lee, Dong Bok Shin, Seung Phil Cho, Jeong Cheol Yoon
J Korean Cancer Assoc. 1997;29(4):706-706.
AbstractAbstract PDF
Metastatic tumor of the epididymis is a rare tumor. There are around 31 cases in the literature until now. The primary tumor was from the prostate in 18 cases, large and small intestine in 6 cases, kidney in 4 cases, stomach in 2 cases and pancreas in 1 case. We recently experienced a case of metastatic carcinoma to the epididymis from a primary cancer in the sigmoid colon and the other case of metastatic carcinoma to the testis and the liver from a sigmoid adenocarcinoma.
  • 2,297 View
  • 20 Download
Close layer
Clinical Trial
Effect of Cytosine Arabinoside and Daunorubicin (AD) Combination Chemotherapy in Acute Myelogenous Leukemia
Yeoung Sook Kang, Hyun Sik Jeong, Tae Seok Kim, Hyun Seon Yun, Deuk Jo Kim, Jeong Ho Yun, Seong Goyng Lee, Hyeon Gyoo Ji, Gui Hyun Ham, Jae Hoon Lee, Dong Bok Shin
J Korean Cancer Assoc. 1997;29(1):160-170.
AbstractAbstract PDF
PURPOSE
Important advances in the treatment of acute myelogenous leukemia have been made with the introduction of cytosine arabinoside (ara-C) and anthracyclines (daunorubicin) over the past 20 years. Currently, 60 to 80% of patients with acute myelogenous leukemia achieve complete remission with induction chemotherapy consisting of ara-C and daunorubicin (adriamycin) AD ("7+3"). The one-fourth of complete responders will have extended long-term survival and may be cured. Therefore wetreated patients with acute myelogenous leukemia admitted to our hospital with AD ("7+3") regimen.
METHODS
Induction therapy; Thirty four patients with previously untreated acute myelogenous leukemia received AD ("7+3") regimen (ara-C, 200 mg/m2/d by continuous infusion for seven days, and daunorubicin, 45 mg/m2/d for 3 days). The second course of therapy was AD ("5+2"), if the patients failed to enter remission. Consolidation therapy; three cycles of consolidation chemotherapy were administered with at least 4 week interval following remission. Course 1; ara-C at 100 mg/m2 by subcutaneous injection every 12 hour for seven days, 6-thioguanine at every 12 hour 100 mg/m2 orally every 12 hour for 7 days). Course 2; ara-C (same as course 1) at 100 mg/m2 by subcutaneous injection every 12 hour for seven days, vincristine at 1.5 mg/m2 (maximum 2 mg) by bolus injection for 1 day, prednisolone at 40 mg/m2 (maximum 60 mg) orally for 7 days. Course 3; ara-C (same as course 1) daunorubicin at 45 mg/m2 by 1 hour infusion for 3 dyas.
RESULTS
Sixty-eight percent of the 34 patients entered complete remission. The remission duration for all patients in complete remission ranged from 4 weeks to 3122+ weeks, with the median of 50 weeks. The median duration of survival in complete responder group was 62 weeks. Twenty-Six percent of patients with complete remission are alive at 5 years.
Case
s with extramedullary leukemic involvement were found in four patients; M2 with orbital mass, M3 and M4 with CNS leukemia, M5a with subcutaneous nodules. Among the potential prognostic variables including age, initial WBC count, percent of blast in peripheral blood,none was statistically related to prognosis.
CONCLUSION
Combination chemotherapy with cytosine arabinoside and daunorubicin is a effective regimen for acute myelogenous leukemia as much as other regimen. Futher clinical trials for effective treatment regimen and method are necessary to raise the complete remission rate.
  • 2,951 View
  • 16 Download
Close layer
Original Articles
Treatment of intermediate-grade non-Hodgkin's lymphoma with CAMP-MOB combination chemotherapy
Chang In Suh, Heung Tae Kim, Dong Bok Shin, Jae Hoon Lee, Dae Seog Heo, Yung Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim
J Korean Cancer Assoc. 1992;24(1):102-108.
AbstractAbstract PDF
No abstract available.
  • 2,585 View
  • 16 Download
Close layer
Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, prednisolone(C-MOPP) in Hodgkin's disease
Kyung Hae Jung, Dong Bok Shin, Hyun Ah Kim, Young Iee Park, Tae You Kim, Keun Chil Park, Yoon Koo Kang, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
J Korean Cancer Assoc. 1991;23(4):806-813.
AbstractAbstract PDF
No abstract available.
  • 2,506 View
  • 24 Download
Close layer
Combination Chemotherapy with Cisplatin , Etoposide , and Vinblastine ( PEV ) in the Advanced Non - Small Cell Lung Cancer
Keun Chil Park, Yoon Koo Kang, Dong Bok Shin, Si Young Kim, Yung Jue Bang, Sung Koo Han, Young Soo Shim, Noe Kyeong Kim, Keun Youl Kim, Keun Youl Kim
J Korean Cancer Assoc. 1989;21(1):82-93.
AbstractAbstract PDF
Fifty patients with the advanced non-small cell lung cancer, who had no previous treatment, were treated with a combination chemotherapy regimen consisting of cisplatin (20mg/m i.v. day 1-5), etoposide (100 mg/m i.v. day 2-4), and vinblastine (6 mg/m(2) i.v, day 1) every 3 weeks. Among the 50 patients entered into this study 45 patients were evaluable for response. Objective responses were achieved in 49 % (22/45) of patients (2 CRs, 20 PRs). In 23 patients with limited disease, the response rate was 61% (14/23) with no complete response, higher than that, but not statistically significant, in the extensive disease patients (36% with 2 CRs). The overall median survival of the patients was 42.6 weeks and the responding patients survived longer than non-responders (median survival; 51.5 weeks vs. 37.4 weeks, p<0.05). Toxicity with this regimen was acceptable; myelosup- pression was the major toxic effect and was severe in only 11% of the patients with one treatment- related death from sepsis associated with granulocytopenia. The gastrointestinal side effects and alopecia were rather universal and the peripheral neuropathy (20%) and azotemia (9%) were not uncommon, but manageable in general.
  • 2,976 View
  • 22 Download
Close layer
Phase 1 Trial of Recombinant Interferon Gamma ( LBD - 001 ) in Cancer Patients
Noe Kyeong Kim, Yung Jue Bang, Dae Seog Heo, Heung Tae Kim, Hyo Jin Kim, Keun Chil Park, Keun Chil Park, Dong Bok Shin, Myung Chul Lee, Byoung Kook Kim, Sang Goo Shin, Seong Hoe Park, Han Ik Cho
J Korean Cancer Assoc. 1990;22(1):86-96.
AbstractAbstract PDF
A phase I study of recombinant gamma-interferon (LBD-001) was conducted in 23 patients with advanced malignancy. The schedule was the intramuscular administration of recombinant interferon-gamma 6 consecutive days a week for 2 weeks followed by 2 weeks of rest and was repeated every 28 days. Patients were assigned to six dose levels. The maximum tolerated dose was 10.0x10(6) units/m/day and the major toxicities were flulike symptoms. After intramuscular injection, the pharmacological data fit the single compartmental modeL More than 2/3 of the dose administered was absorbed. The absorbance T 1/2 was longer with values of 247.6 minutes but interferon-gamma was cleared with a short half life of 49.9 minutes from the circulation. Antitumor effects occurred in patients with chronic myelogenous leukemia and malignant melanoma.
  • 2,665 View
  • 19 Download
Close layer
Microangiopathic Hemolytic Anemia ( MAHA ) Associated with Cancer
Keun Chil Park, Dong Bok Shin, Keun Chil Park, Jae Hoon Lee, Yung Jue Bang, Seon Yang Park, Byoung Kook Kim, Noe Kyeong Kim
J Korean Cancer Assoc. 1990;22(1):183-194.
AbstractAbstract PDF
MAHA has been recognized as an uncommon, but fatal complication of cancer or its chemotherapy. From May, 1982 to Sep., 1988, we have experienced 29 cases of MAHA in cancer patients, of which 23 were thought to be cancer-associated and 6 to be chemotherapy-related. The clinical characteristica of MAHA in these patients are presented. Adenocarcinoma of the stomach was the most common primary cancer in cancer-associated MAHA. Mitomycin-C(MMC) was thought to be an offending agent of chemotherapy-related MAHA, and cumulative dose of MMC was 32-190 mg(mean 117 mg). Most patients presented abruptly with anemia or bleeding tendency. In some patients with chemotherapy-related MAklA, pulmonary edema or seizure was also observed. The most consistent laboratory findings were hemolytic anemia with characteristic schistocytes in the peripheral blood smear and thrombocytopenia. The most characteristic finding in cancer-associated MAHA was leukoerythroblastosis which was present in 74% of the patients, and that in chemotherapy-related MAHA was azotemia with microscopic hematuria or proteinuria which characterized the chemotherapy-related MAHA as chemotherapy-related hemolytic uremic syndrome (HUS). While MAHA was rapidly fatal in most patients managed with supportive treatment only, improve- ment of MAHA with partial response of cancer was achieved in 4 among 9 patients treated with FP (5-fluorouracil+cisplatin) chemotherapy. In case of chemotherapy-related MAHA, we treated 3 patients with plasmapheresis and MAHA was improved but azotemia was not. In conclusion, MAHA in cancer could be classified into cancer-associated MAHA and chemotherapy-related HUS. An early differential diagnosis and aggressive treatment could improve the prognosis of these previousiy fatal syndromes.
  • 4,835 View
  • 47 Download
Close layer
A Case of Multiple Cutaneous Metastasis from Gastric Adenocarcinoma
Hun Sik Jeong, Kwang Ho Kim, Yeon Suk Kim, In Suk Song, Dong Gu Choi, Dong Bok Shin
J Korean Cancer Assoc. 1995;27(5):893-897.
AbstractAbstract PDF
Cutaneous multiple metastases from internal carcinoma are relatively rare, especially from gastric cercinoma. We report a case of multiple cutaneous metastasis from gastric adenocarcinoma in 51 year old male patient who have multiple variable sized erythromatous nodules and macule on the trunk, left axilla, and right thigh.
  • 2,532 View
  • 15 Download
Close layer
A Case of Acute Lymphocytic Leukemia in Adolescent Down Syndrome
Se Jin Oh, Kwang Ho Kim, Hun Sik Jeong, Dong Gu Choi, Dong Bok Shin, Wan Kim
J Korean Cancer Assoc. 1996;28(1):182-190.
AbstractAbstract PDF
Adolescent Down syndrome with leukemia is very rare and distinctive disease. The association of Down syndrome and leukemia has been documented for over 50 years. The age of onset for leukemia in this disease is bimadal, peaking first in the newborn period and again at 36 years. The association risk of these two conditions-Down syndrome and leukemia - is about 10- to 20-fold higher than in the general population. This increased risk extends into adulthood. Down syndrome associated with acute leukemia has usually poor prognosis, but some cases went to spontaneous remission in previously published papers. The proportion of acute leukemia type of these patients shows no difference compared to non-Down syndrome leukemia. A 20 year old male patient was admitted to our hospital due to frequent common cold history and recently developed periumbilical pain and poor oral intake. He was born second of 5 siblings from normal parents by normal spontaneous vaginal delivery. Conaenital appearance was mongoloid face and simian crease in both hands. The facial appearance was hyperteloric eyes and opened mouth and small face, flat nose at a glance. His CBC showed severe anemia and abnormal leukocyte counts with differential counts. So he was admitted to Hemato-Oncology department of internal medicine and then we carefully did physical examination and laboratory tests. His clinical features, peripheral blood smear and bone marrow aspiration-cytology and biposy revealed acute lymphocytic leukemia (ALL) Ll subtype. The chromosome study revealed 47, XY, +21 in karyotype. Thus, he was diagnosed as ALL with Down syndrome. Treatment was not given to this patient due to incorporation of patient because of retarded mentality. The patient was expired about 4 month's later. Thus, we report the first case of acquired ALL in adolescent Down syndrome in Korea,
  • 2,559 View
  • 14 Download
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP